1. Scrip
  2. >>Business
  3. >>Earnings

Vertex Gears Up For Major Milestones, Starting With Sickle Cell Launch And Pain Drug Readout

 
• By Andrew McConaghie

Having long attracted investors thanks to its promising pipeline, the moment of truth approaches for Vertex’s sickle cell gene therapy exo-cel, and VX-548, which has potential to transform acute and chronic pain treatment.

Vertex HQ, Boston

Vertex is gearing up for a string of major milestones in the coming months which could see it bring two groundbreaking medicines to market in 2024 – its sickle cell disease gene therapy and a first-in-class non-opioid pain medication.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Gilead Keeping Eye On Policy But Sees Little Impact From HHS Cuts, Tariffs

 
• By Alaric DeArment

The drugmaker said in its first quarter earnings that it did not foresee negative effects on potential approval and launch of lenacapavir for PrEP later this year.

Merck Forecast Incorporates $200m Tariff Hit

 
• By Joseph Haas

On a quarterly earnings call that touched on Trump administration policy impacts, Merck said it is well positioned for changes coming from the new administration.

BMS Keeping A Watchful Eye On Tariffs, Pricing And Other Policy Changes

 
• By Mandy Jackson

Bristol Myers Squibb’s first quarter revenue beat consensus and the company raised its 2025 guidance, even when including the impact of Chinese tariffs on US products.

Sanofi Spends Big In US But Offers Crumbs Of Comfort For Europe

 
• By Kevin Grogan

CFO François Roger tells Scrip the French drugmaker is flexible geographically on making investments but its spend in the US has risen regardless of the threat of tariffs.

More from Business

Sanofi Spends Big In US But Offers Crumbs Of Comfort For Europe

 
• By Kevin Grogan

CFO François Roger tells Scrip the French drugmaker is flexible geographically on making investments but its spend in the US has risen regardless of the threat of tariffs.

Roche Moves To Soften Tariff Blow But Admits M&A Dealmaking Could Be Hit

 
• By Andrew McConaghie

Roche believes it can ride out any short-term effects of US tariffs if they are imposed but wants to see reform of US and European pricing to help support the sector.

In Brief: Boehringer Ingelheim, Tessellate Bio Link For Precision Therapies For ALT Tumors

 
• By Sushmita Panda

In its first pharma collaboration, Tessellate Bio has inked a deal potentially worth more than €500m with Boehringer Ingelheim for therapies for ALT tumors.